Ubiquitin/proteasomsystemet vid neurodegenerativa sjukdomar och cancer – Nico Dantumas forskargrupp

Våra huvudsakliga mål är att förstå vilken roll ubiquitin/proteasomsystemet spelar i utvecklingen av neurodegenerativa sjukdomar och cancer samt att undersöka den terapeutiska potentialen hos ämnen som påverkar detta system.

En del av:

Publikationer

Utvalda publikationer

Finansiering

Forskningsbidrag

  • Targeting the ubiquitin-proteasome system in cancer
    Swedish Cancer Society
    1 januari 2025 - 31 december 2027
  • Swedish Research Council
    1 januari 2025 - 31 december 2027
    The removal of misfolded or otherwise damaged proteins from the intracellular environment is of critical importance for cells as these aberrant proteins can give rise to toxic protein aggregates. The main proteolytic mechanism for the destruction of misfolded proteins is the ubiquitin-proteasome system (UPS), which is a central player in cellular protein quality control. The UPS is a complex machinery involving hundreds of different proteins, many of which have distinct enzymatic activities and are, therefore, potentially druggable targets. In recent years, both inhibition and stimulation of the UPS have gained credit as means for therapeutic intervention in human diseases. Malignant cells typically produce high levels of misfolded proteins, which render them exquisitely sensitive to drugs that inhibit UPS activity. On the other hand, stimulation of the UPS may prevent the accumulation of aggregation-prone proteins in neurons, which plays a central role in a variety of age-related, neurodegenerative disorders, such as Alzheimer’s disease. We have previously established tools for the monitoring of UPS activity in normal and malignant cells and started a drug discovery campaign for UPS inhibitors. Here we propose 1) to study the mode of action of a novel inhibitor of the UPS with anti-tumor properties, 2) explore the potential of two cellular targets for stimulating the UPS and 3) inveistigate the status of the UPS in human embryonic stem cell-derived neuronal lineages.
  • Hjärnfonden
    1 juli 2023 - 30 juni 2025
  • Swedish Research Council
    1 januari 2022 - 31 december 2024
  • Swedish Cancer Society
    1 januari 2022
    Dysfunctional protein degradation plays an important role in cancer. Marking proteins with ubiquitin is central to protein degradation because it stimulates specific protein degradation. Substances that inhibit the function of ubiquitin in protein degradation can be used to kill cancer cells. Slowing down protein breakdown is a relatively new way of cancer treatment. In this project, we plan to identify new molecular targets and develop new substances to slow protein degradation in cancer cells. In a genetic screen, we have identified genes that stimulate or slow down protein degradation. We want to understand how they work and whether they could be used to modify protein degradation for a therapeutic purpose. We will also investigate two new substances that we have identified in screens for their potential to slow down protein degradation. We have seen that these substances are toxic to cancer cells. Our goal is to understand how they kill cancer cells and to study their activity in a mouse model. We want to develop substances that slow down ubiquitin-dependent processes into drugs that block protein degradation in different ways. Blocking protein degradation is a relatively new strategy for anti-cancer therapy. So far, there are only a few approved anti-cancer drugs that work this way. They have been used for a couple of years now for the treatment of multiple myeloma.
  • Target identification of a novel inhibitor of the ubiquitin-proteasome system and autophagy
    Novo Nordisk Foundation
    1 april 2020 - 31 mars 2021
  • In vivo validation of a novel inhibitor of the ubiquitin/proteasome system
    Novo Nordisk Foundation
    1 augusti 2019 - 31 juli 2020
  • Deutsche Forschungsgemeinschaft
    1 januari 2018 - 31 december 2021
  • Deutsche Forschungsgemeinschaft
    1 januari 2018 - 31 december 2021
  • Swiss National Science Foundation
    1 april 2016 - 31 mars 2019

Medarbetare och kontakt

Gruppledare

Alla medarbetare i gruppen